On November 18, the Anhui Provincial Drug Administration decided on the administrative penalty decision of Anhui Weiwu Traditional Chinese Medicine Tablet Technology Co., Ltd. on the 10th, and imposed a fine of 345,488.96 yuan on the company's production and sale of unqualified drugs. It is understood that at the end of last year, the company was ordered to rectify within a time limit due to serious defects in drugs.
The administrative penalty decision made by the Anhui Provincial Drug Administration on November 10 pointed out that the Zhejiang shellfish produced and sold by Anhui Weiwu Chinese Medicine Tablet Technology Co., Ltd. was unqualified by the Shaoxing Food and Drug Inspection and Research Institute, and the report number: YPY202100531. In accordance with the provisions of Article 117 of the Drug Administration Law of the People's Republic of China, the Anhui Provincial Food and Drug Administration has decided to impose the following penalties on Anhui Weiwu Chinese Medicine Tablet Technology Co., Ltd.:
1. Confiscate 84kg of unqualified Zhejiang shellfish;
2. Confiscation of illegal gains of Jiu Wan Wu Qian Qian Bai Bao Bai Pick Up Point Jiu Wu Yuan (95488.95 yuan);
3. Fined 20,000 yuan (250,000.00 yuan);
The total amount of fines and forfeitures is 30,000 yuan (345,488.95 yuan).
China Net Finance noted that this is not the first time that Anhui Weiwu Chinese Medicine Tablet Technology Co., Ltd. has been punished by the regulatory authorities for the case of unqualified drugs.
On January 15 this year, the Anhui Provincial Drug Administration pointed out in the notice of the daily supervision and inspection information of the province at the provincial level for the production of Traditional Chinese Medicine Tablets (including Chinese Medicine Formula Granules) in December 2020 that the drugs produced by Anhui Weiwu Chinese Medicine Tablets Technology Co., Ltd. had 1 serious defect, 1 major defect and 10 general defects, which did not meet the requirements of GMP (Good Manufacturing Practice for Drugs), and the second branch of the Anhui Provincial Food and Drug Administration warned the company, interviewed and ordered it to rectify within a time limit.
According to the data, Anhui Weiwu Chinese Medicine Tablet Technology Co., Ltd. is an enterprise registered in Bozhou, the capital of medicine, and the current legal representative and general manager is Li Yang.
For the drug problems exposed by Anhui Weiwu Chinese Medicine Tablet Technology Co., Ltd., China Net Finance will continue to pay attention to them.
(Editor-in-charge: Zhao Rong)